KRAS and cancer: The recent meta-analysis by Formica et al. [34] suggests that tumors with mutations in BRAF/KRAS in the MSS context exhibit a more aggressive tumor biology, which is evident from the early stages of cancer growth and persisting into the metastatic stage.